This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Crabtree, G. R. Articles by Munck, A. Search for Related Content PubMed PubMed Citation Articles by Crabtree, G. R. Articles by Munck, A.

Glucocorticoid Receptors and in Vitro Responses to Glucocorticoid in Acute Nonlymphocytic Leukemia¹

Departments of Physiology [G. R. C., and A. M.] and Medicine [K. A. S., L. H.], Dartmouth Medical School, Hanover, New Hampshire 03755, and Section of Medical Oncology, Department of Medicine [C. D. B., B. A. P.], and Department of Laboratory Medicine and Pathology [R. W. M.], University of Minnesota Health Sciences Center, Minneapolis, Minnesota 55455

Early clinical studies in which glucocorticoids were used alone in the treatment of acute nonlymphocytic leukemia (ANLL) reported a wide range of responses from remission in some patients to dramatic aggravation of the disease in others. In the hopes of identifying those patients likely to derive therapeutic benefit from glucocorticoids, we have studied glucocorticoid receptors and in vitro responses to glucocorticoids in 36 previously untreated adults with ANLL. The leukemic blasts of all patients contained glucocorticoid receptors (range, 4,300 to 28,400 total receptor sites per cell; median, 8,800). These receptors were similar in all respects studied to those from a variety of other normal and malignant tissues. There was little difference between receptor levels among the various French-American-British categories. In vitro responses to glucocorticoid were observed in leukemic blasts of 26 of 28 cases studied. These responses varied from near complete cell killing to stimulation of proliferation. Since the cells of patients with ANLL have about the same number of receptors as do cells from patients with acute lymphoblastic leukemia and these receptors are capable of mediating physiological responses in vitro, it is unlikely that qualitative or quantitative receptor defects underlie the relative resistance to glucocorticoid therapy of ANLL compared to acute lymphoblastic leukemia. However, the broad range of in vitro responses and receptor levels suggests that these studies might be useful in identifying those patients with ANLL likely to derive benefit from steroid therapy.

¹ Presented at the Conference on Cell Markers in Acute Leukemia, March 4 and 5, 1980, Bethesda, Md. Supported in part by USPHS Grants CA-26273, CA-17323, and AM-03535, the Masonic Hospital Fund, Inc., the Norris Cotton Cancer Center, the Minnesota Medical Foundation, and American Cancer Society Grant CH-167.

² To whom requests for reprints should be addressed, at Laboratory of Biochemistry, Building 10, Room 2N108, National Cancer Institute, Bethesda, Md. 20205.